Randomized Controlled Trial of Ethyl-Eicosapentaenoic Acid in Huntington Disease The TREND-HD Study

E. R. Dorsey; I. Shoulson; B. Leavitt; C. Ross; C. A. Beck; E. A. de Blieck; J. T. Greenamyre; S. M. Hersch; K. Kieburtz; K. Marder; C. McCallum; C. Moskowitz; D. Oakes; A. Rosenblatt; A. Shinaman; S. Frucht; R. Margolis; J. Corey-Bloom; L. Mook; K. Shannon; J. Jaglin; J. Sanchez-Ramos; L. S. Dure; M. Guttman; A. Feigin; B. Shannon; K. E. Anderson; B. A. Racette; D. Higgins; P. Agarwal; L. Seeberger; S. Montellano; S. Kostyk; A. Seward; M. Nance; L. A. Raymond; J. Decolongon; O. Suchowersky; L. Beglinger; P. Como; H. Paulson; R. Barbano; C. Zimmerman; J. Wojcieszek; M. Jog; C. Horn; A. Colcher; M. D. Geschwind; R. M. Dubinsky; W. Martin; M. Wieler; M. S. LeDoux; M. B. Harrison; J. C. Morgan; B. Dill; C. Singer; M. Quesada; N. Kartha; K. Wernette; S. Frank; H. Fernandez; D. Jennings; T. Kelsey; C. Hunter; K. Bourgeois; L. Deuel; N. McMullen; V. Ross; L. Rumfola; A. Watts; C. Weaver; T. Winebrenner; P. N. Tariot; Huntington Study Group TREND-HD Investigators

doi:10.1001/archneur.65.12.1582

Back

Randomized Controlled Trial of Ethyl-Eicosapentaenoic Acid in Huntington Disease The TREND-HD Study

Journal article

Peer reviewed

Randomized Controlled Trial of Ethyl-Eicosapentaenoic Acid in Huntington Disease The TREND-HD Study

E. R. Dorsey, I. Shoulson, B. Leavitt, C. Ross, C. A. Beck, E. A. de Blieck, J. T. Greenamyre, S. M. Hersch, K. Kieburtz, K. Marder, …

Archives of neurology (Chicago), Vol.65(12), pp.1582-1589

12/01/2008

DOI: 10.1001/archneur.65.12.1582

PMID: 19064745

View Online

Abstract

Objective: To determine whether ethyl-eicosapentaenoic acid (ethyl-EPA), an omega-3 fatty acid, improves the motor features of Huntington disease. Design: Six-monthmulticenter, randomized, double-blind, placebo-controlled trial followed by a 6-month open-label phase without disclosing initial treatment assignments. Setting: Forty-one research sites in the United States and Canada. Patients: Three hundred sixteen adults with Huntington disease, enriched for a population with shorter trinucleotide (cytosine-adenine-guanine) repeat length expansions. Interventions: Random assignment to placebo or ethyl-EPA, 1 g twice a day, followed by open-label treatment with ethyl-EPA. Main Outcome Measures: Six-month change in the Total Motor Score 4 component of the Unified Huntington's Disease Rating Scale analyzed for all research participants and those with shorter cytosine-adenine-guanine repeat length expansions (< 45). Results: At 6 months, the Total Motor Score 4 point change for patients receiving ethyl-EPA did not differ from that for those receiving placebo. No differences were found in measures of function, cognition, or global impression. Before public disclosure of the 6-month placebo-controlled results, 192 individuals completed the open-label phase. The Total Motor Score 4 change did not worsen for those who received active treatment for 12 continuous months compared with those who received active treatment for only 6 months (2.0-point worsening; P=.02). Conclusion: Ethyl-EPA was not beneficial in patients with Huntington disease during 6 months of placebo-controlled evaluation.

Clinical Neurology

Life Sciences & Biomedicine

Neurosciences & Neurology

Science & Technology

Details

Title: Subtitle: Randomized Controlled Trial of Ethyl-Eicosapentaenoic Acid in Huntington Disease The TREND-HD Study
Creators: E. R. Dorsey - Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14620 USA
I. Shoulson
B. Leavitt
C. Ross
C. A. Beck
E. A. de Blieck
J. T. Greenamyre
S. M. Hersch
K. Kieburtz
K. Marder
C. McCallum
C. Moskowitz
D. Oakes
A. Rosenblatt
A. Shinaman
S. Frucht - Columbia University
R. Margolis - Johns Hopkins University
J. Corey-Bloom - Univ Calif San Diego, La Jolla, CA 92093 USA
L. Mook - Massachusetts Gen Hosp, Charlestown, MA USA
K. Shannon - Rush University
J. Jaglin - Rush University
J. Sanchez-Ramos - Univ S Florida, Tampa, FL USA
L. S. Dure - Univ Alabama Birmingham, Birmingham, AL USA
M. Guttman - Ctr Movement Disorders, Markham, ON, Canada
A. Feigin - N Shore Long Isl Jewish Hlth Syst, Manhasset, NY USA
B. Shannon - N Shore Long Isl Jewish Hlth Syst, Manhasset, NY USA
K. E. Anderson - Washington University in St. Louis School of Medicine
B. A. Racette - Washington Univ, St Louis, MO USA
D. Higgins - Albany Med Coll, Albany, NY 12208 USA
P. Agarwal - Colorado Neurol Inst, Englewood, CO USA
L. Seeberger - Colorado Neurol Inst, Englewood, CO USA
S. Montellano - Colorado Neurol Inst, Englewood, CO USA
S. Kostyk - Ohio State Univ, Columbus, OH 43210 USA
A. Seward - Ohio State Univ, Columbus, OH 43210 USA
M. Nance - Struthers Parkinsons Ctr, Golden Valley, MN USA
L. A. Raymond - Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
J. Decolongon - Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
O. Suchowersky - Univ Calgary, Calgary, AB, Canada
L. Beglinger - Univ Iowa, Iowa City, IA USA
P. Como
H. Paulson - Univ Iowa, Iowa City, IA USA
R. Barbano
C. Zimmerman
J. Wojcieszek - Indiana University
M. Jog - London Hlth Sci Ctr, London, ON, Canada
C. Horn - London Hlth Sci Ctr, London, ON, Canada
A. Colcher - Univ Penn, Philadelphia, PA 19104 USA
M. D. Geschwind - Univ Calif San Francisco, San Francisco, CA 94143 USA
R. M. Dubinsky - Univ Kansas, Med Ctr, Kansas City, KS USA
W. Martin - Univ Alberta, Edmonton, AB, Canada
M. Wieler - Univ Alberta, Edmonton, AB, Canada
M. S. LeDoux - Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA
M. B. Harrison - Univ Virginia, Charlottesville, VA USA
J. C. Morgan - Med Coll Georgia, Augusta, GA 30912 USA
B. Dill - Med Coll Georgia, Augusta, GA 30912 USA
C. Singer - Univ Miami, Miami, FL USA
M. Quesada - Univ Miami, Miami, FL USA
N. Kartha - Univ Michigan, Ann Arbor, MI 48109 USA
K. Wernette - Univ Michigan, Ann Arbor, MI 48109 USA
S. Frank - Boston University
H. Fernandez - Univ Florida, Gainesville, FL USA
D. Jennings - Inst Neurodegenerat Disorders, New Haven, CT USA
T. Kelsey - Inst Neurodegenerat Disorders, New Haven, CT USA
C. Hunter - Baylor Coll Med, Houston, TX 77030 USA
K. Bourgeois
L. Deuel
N. McMullen
V. Ross
L. Rumfola
A. Watts
C. Weaver
T. Winebrenner
P. N. Tariot - Phoenix (United States)
Huntington Study Group TREND-HD Investigators
Contributors: D Langbehn (Contributor) - University of Iowa, Psychiatry
Resource Type: Journal article
Publication Details: Archives of neurology (Chicago), Vol.65(12), pp.1582-1589
DOI: 10.1001/archneur.65.12.1582
PMID: 19064745
NLM abbreviation: Arch Neurol
ISSN: 0003-9942
eISSN: 1538-3687
Publisher: American Medical Association
Number of pages: 8
Grant note: University of Rochester
Language: English
Date published: 12/01/2008
Academic Unit: Psychiatry; Iowa Neuroscience Institute
Record Identifier: 9984293756202771

Metrics

6 Record Views

86 Times Cited - Web of Science

See more details